Hepatic and Renal Responses to Mesenchymal Stromal Cell Therapy: Mechanisms and Biochemical Evidence

Mesenchymal stromal cell (MSC) therapy is being investigated for hepatic and renal disorders, but biochemical changes do not necessarily establish organ regeneration or clinical benefit. This non-exhaustive narrative review evaluates direct MSC interventions and six blood analytes: alanine aminotransferase, aspartate aminotransferase, total bilirubin, total protein, urea, and creatinine. PubMed-indexed English-language studies published from 2000 through 11 October 2026 were considered when complete texts and relevant findings were accessible; reviews and methodological sources provide background. Evidence is interpreted by species, disease, specimen, cell product, comparison type, and follow-up. Proposed mechanisms include paracrine signaling, immunomodulation, and host responses to administered cells, with varying experimental support. Selected preclinical studies report biochemical improvements, whereas human findings are heterogeneous. Serum total-protein responses are limited and product-dependent, and direct serum-urea evidence is mainly preclinical. The ACT-AKI trial found no acceleration of creatinine-defined recovery, while a randomized cirrhosis follow-up showed a within-arm bilirubin decline without a significant between-group difference. Urea nitrogen, albumin, urinary protein, and filtration outcomes are distinguished from the specified concentrations. Findings are synthesized descriptively, with explicit source uncertainties. Standardized cell characterization and controlled trials combining biochemical, histological, and functional outcomes are needed to assess durable clinical benefit.

Authors

Institutions

Publication Details

Journal
Biology
Published
2026-11-18
DOI
https://doi.org/10.3390/biology15222113
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hepatic and Renal Responses to Mesenchymal Stromal Cell Therapy: Mechanisms and Biochemical Evidence

D Tarzhanova, Nursulu Altaeva, Balkiya Abdrakhmanova, Ardak Sapiyeva et al.
Biology
Mesenchymal stem cell research
article

Hepatic and Renal Responses to Mesenchymal Stromal Cell Therapy: Mechanisms and Biochemical Evidence

D Tarzhanova, Nursulu Altaeva, Balkiya Abdrakhmanova, Ardak Sapiyeva, Baglan Kazhiyakhmetova, Aizhan Akhayeva, Anastasia Ganina, Tanzira Yedilbayeva, Aigerim K. Zhakupova, Anuar Z. Zhunusov, Elmira K. Chuvakova, Abylay K. Mussin, Tatyana S. Bulavinceva, Anna I. Goncharenya, Beksultan K. Mussin, Sapargul Marat
article en

Abstract

Mesenchymal stromal cell (MSC) therapy is being investigated for hepatic and renal disorders, but biochemical changes do not necessarily establish organ regeneration or clinical benefit. This non-exhaustive narrative review evaluates direct MSC interventions and six blood analytes: alanine aminotransferase, aspartate aminotransferase, total bilirubin, total protein, urea, and creatinine. PubMed-indexed English-language studies published from 2000 through 11 October 2026 were considered when complete texts and relevant findings were accessible; reviews and methodological sources provide background. Evidence is interpreted by species, disease, specimen, cell product, comparison type, and follow-up. Proposed mechanisms include paracrine signaling, immunomodulation, and host responses to administered cells, with varying experimental support. Selected preclinical studies report biochemical improvements, whereas human findings are heterogeneous. Serum total-protein responses are limited and product-dependent, and direct serum-urea evidence is mainly preclinical. The ACT-AKI trial found no acceleration of creatinine-defined recovery, while a randomized cirrhosis follow-up showed a within-arm bilirubin decline without a significant between-group difference. Urea nitrogen, albumin, urinary protein, and filtration outcomes are distinguished from the specified concentrations. Findings are synthesized descriptively, with explicit source uncertainties. Standardized cell characterization and controlled trials combining biochemical, histological, and functional outcomes are needed to assess durable clinical benefit.

BiologyVol. 15(22)
Semmelweis University (HU), National Medical Holding (KZ), Astana Medical University (KZ), National Research Center for Maternal and Child Health (KZ)
Good health and well-being
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon